Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SLC-3010 |
Synonyms | |
Therapy Description |
SLC-3010 is a conjugate of IL-2 linked to an anti-IL2 antibody, which potentially induces increased antitumor immune response and inhibits tumor growth (Cancer Res (2021) 81 (13_Supplement): 689). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SLC-3010 | SLC 3010|SLC3010 | SLC-3010 is a conjugate of IL-2 linked to an anti-IL2 antibody, which potentially induces increased antitumor immune response and inhibits tumor growth (Cancer Res (2021) 81 (13_Supplement): 689). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05525247 | Phase Ib/II | Gemcitabine + SLC-3010 SLC-3010 | A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination | Recruiting | USA | AUS | 1 |